Kymera Therapeutics (KYMR) PT Raised to $97 at Brookline Capital Markets
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $119.05 +0.20%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
Brookline Capital Markets analyst Leah Rush Cann raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $97.00 (from $90.00) while maintaining a Buy rating.
You May Also Be Interested In
- Kymera Therapeutics (KYMR) PT Raised to $170 at Guggenheim
- Science Applications (SAIC) PT Raised to $140 at Jefferies
- Designer Brands (DBI) PT Lowered to $6 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
